Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA approves new Claritin label

This article was originally published in The Tan Sheet

Executive Summary

FDA will allow Schering-Plough to communicate on its product label that Claritin relieves both indoor and outdoor allergies, potentially extending the OTC non-drowsy allergy medicine's benefits beyond seasonal allergy treatment. Previously, labels could only state that Claritin relieves outdoor allergies, S-P says Jan. 22...

You may also be interested in...



Claritin label change

FDA approves Schering-Plough's request to add the descriptor "Indoor & Outdoor Allergies" to the principal display panel of 10- and 30-count carton labels of Claritin Liqui-Gels (loratadine 10 mg), according to an April 6 letter. The change could extend the medicine's benefits beyond seasonal allergies. FDA approved a similar change to Claritin packaging in 2008 (1"The Tan Sheet" Jan. 28, 2008, In Brief)

QUOTED. 2 March 2021. Michael Coyle.

Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.

Medicare Drug Pricing Demonstration Agenda May Be Reshaped By Fowler As CMMI Head

Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel